Activity of faropenem against cephalosporin-resistant Enterobacteriaceae
Activity of faropenem against cephalosporin-resistant Enterobacteriaceae
复制标题
DOI：
10.1093/jac/dkm063
复制
发表时间：
2007-05-01
影响因子：
5.2
通讯作者：
Livermore, David M.
中科院分区：
文献类型：
--
作者：
Mushtaq, Shazad;Hope, Russell;Livermore, David M.
Background. There is a need for new oral agents active against extended-spectrum beta-lactamase (ESBL) producers, as these increasingly cause community-onset infections. We therefore evaluated faropenem, a penem in Phase III development, against recently collected oxyimino-cephalosporinresistant bacteria.Methods: We tested 847 consecutive cephalosporin-resistant Enterobacteriaceae collected at 16 centres in South-East England in 2004, 501 of them with CTX-M enzymes; we also tested reference strains and transconjugants with acquired beta-lactamases and various modes of AmpC expression. MICs were determined by the BSAC agar dilution method.Results: Modal MICs of faropenem for Escherichia coli or Klebsiella spp. with CTX-M or non-CTX-M ESBLs or high-level AmpC enzyme were 0.5-1 mg/L, with over 95% of producers susceptible to
